Skip to main content
Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies
- Author(s): Marks, James
- D'Souza, JW
- Reddy, S
- Goldsmith, LE
- Shchaveleva, I
- Marks, JD
- Litwin, S
- Robinson, MK
- et al.
Published Web Location
http://europepmc.org/articles/PMC4227695?pdf=renderNo data is associated with this publication.
Abstract
© 2014 D'Souza et al.Background: Inappropriate signaling through the epidermal growth factor receptor family (EGFR1/ERBB1, ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4) of receptor tyrosine kinases leads to unregulated activation of multiple downstream signaling
Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.